Close Menu

NEW YORK – Interpace Biosciences has experienced a busy year in both diagnostic development and biopharma services, including securing insurance coverage for multiple tests, a business acquisition, and a company rebranding to reflect the resulting expansion.

The Parsippany, New Jersey-based firm now aims to expand current relationships with multiple biopharmaceutical companies as it bolsters its service offerings for cancer therapeutics firms and, eventually, drug developers in other disease indications. 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.